ClinicalTrials.gg
RecruitingNCT06911112Updated Aug 11, 2026

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Phase 3 interventional study of NBI-1065845 and Placebo in Major Depressive Disorder, sponsored by Neurocrine Biosciences. Recruiting at 39 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Depressive Disorder, Major by Neurocrine Biosciences — 6 open to participants now, 6 under way, 5 of them phase 3. Depressive Disorder, Major · Neurocrine Biosciences.

Planned enrollment
3rd of 10
200 · median 192
Started
2025
with 5 others
Phase 3
5 of 10
5 open now
Registered
6th of 10
by date

Among the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, this one is the 3rd largest by planned enrollment, is one of 6 that started in 2025, is one of 5 in phase 3, and was the 6th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

6 of the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • MDD
  • Depression
  • Major Depressive Disorder
  • NBI-1065845
  • TAK-653
  • MADRS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.
  • Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.
  • Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.
  • Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1).
  • Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.

Key Exclusion Criteria:

  • A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.
  • Are considered by the investigator to be at imminent risk of suicide or injury to self or others.
  • Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    NBI-1065845

    NBI-1065845 administered orally once a day.

    Drug: NBI-1065845

  • Placebo comparator
    Placebo

    Placebo identical in appearance to NBI-1065845 will be administered orally once a day.

    Drug: Placebo

Interventions

  • NBI-1065845 tablets

    Also known as: TAK-653

  • DrugPlacebo

    Matching placebo tablets

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56

    Time frame: Baseline, Day 56

Secondary outcomes

  1. Change from Baseline in Sheehan Disability Scale (SDS) Total Score at Day 56

    Time frame: Baseline, Day 56

  2. Change from Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Day 56

    Time frame: Baseline, Day 56

07

Study locations

34 of 39 sites recruiting
  • Neurocrine Clinical Site
    Huntsville, Alabama 35801, United States
    Recruiting
  • Neurocrine Clinical Site
    Bryant, Arkansas 72022, United States
    Recruiting
  • Neurocrine Clinical Site
    Glendale, California 91206, United States
    Recruiting
  • Neurocrine Clinical Site
    Irvine, California 92614, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Redlands, California 92373, United States
    Recruiting
  • Neurocrine Clinical Site
    San Francisco, California 94107, United States
    Recruiting
  • Neurocrine Clinical Site
    Hollywood, Florida 33024, United States
    Recruiting
  • Neurocrine Clinical Site
    Miami, Florida 33174, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Tampa, Florida 33634, United States
    Recruiting
  • Neurocrine Clinical Site
    Atlanta, Georgia 30318, United States
    Recruiting
  • Neurocrine Clinical Site
    Boston, Massachusetts 02131, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Saint Charles, Missouri 63304, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    New York, New York 10029, United States
    Recruiting
  • Neurocrine Clinical Site
    The Bronx, New York 10461, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Mason, Ohio 45040, United States
    Recruiting
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
    Recruiting
  • Neurocrine Clinical Site
    Charlottesville, Virginia 22903, United States
    Recruiting
  • Neurocrine Clinical Site
    Kardzhali, 6600, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Plovdiv, 4004, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Rousse, 7003, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1113, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1510, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Varna, 9020, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Kaunas, LT-44279, Lithuania
    Recruiting
  • Neurocrine Clinical Site
    Kaunas, LT-49449, Lithuania
    Recruiting
  • Neurocrine Clinical Site
    Kaunas, LT-53137, Lithuania
    Recruiting
  • Neurocrine Clinical Site
    Klaipėda, LT-91251, Lithuania
    Recruiting
  • Neurocrine Clinical Site
    Vilnius, LT-10309, Lithuania
    Recruiting
  • Neurocrine Clinical Site
    Bucharest, 041914, Romania
    Recruiting
  • Neurocrine Clinical Site
    Bucharest, 60222, Romania
    Recruiting
  • Neurocrine Clinical Site
    Craiova, 200157, Romania
    Recruiting
  • Neurocrine Clinical Site
    Oradea, 410154, Romania
    Recruiting
  • Neurocrine Clinical Site
    Banská Bystrica, 974 01, Slovakia
    Recruiting
  • Neurocrine Clinical Site
    Bojnice, 972 01, Slovakia
    Recruiting
  • Neurocrine Clinical Site
    Bratislava, 820 07, Slovakia
    Recruiting
  • Neurocrine Clinical Site
    Košice, 040 01, Slovakia
    Recruiting
  • Neurocrine Clinical Site
    Rimavská Sobota, 979 01, Slovakia
    Recruiting
  • Neurocrine Clinical Site
    Svidník, 089 01, Slovakia
    Recruiting
  • Neurocrine Clinical Site
    Vranov nad Topľou, 093 01, Slovakia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jul 2027, 28 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 28 months is close to that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06911112
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Mar 31, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

Neurocrine Medical Information Call Center
Contact
medinfo@neurocrine.com
1-877-641-3461
Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osavampator

Start the discussion